China Universal Asset Management Co. Ltd. Purchases 909 Shares of United Therapeutics Co. (NASDAQ:UTHR)

China Universal Asset Management Co. Ltd. lifted its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 10.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,466 shares of the biotechnology company's stock after purchasing an additional 909 shares during the quarter. China Universal Asset Management Co. Ltd.'s holdings in United Therapeutics were worth $3,340,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. USA Financial Formulas purchased a new position in shares of United Therapeutics in the third quarter worth $33,000. Brooklyn Investment Group bought a new stake in shares of United Therapeutics in the third quarter worth $33,000. Capital Performance Advisors LLP bought a new stake in shares of United Therapeutics in the third quarter worth $82,000. MassMutual Private Wealth & Trust FSB grew its holdings in shares of United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 58 shares during the period. Finally, Values First Advisors Inc. bought a new stake in shares of United Therapeutics in the third quarter worth $90,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insiders Place Their Bets

In related news, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $353.64, for a total transaction of $3,536,400.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $911,330.28. This trade represents a 79.51 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Judy D. Olian sold 1,750 shares of the business's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $412.48, for a total transaction of $721,840.00. Following the sale, the director now directly owns 5,655 shares of the company's stock, valued at $2,332,574.40. This represents a 23.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 143,838 shares of company stock worth $53,981,956 in the last 90 days. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Up 0.1 %

UTHR stock traded up $0.35 during mid-day trading on Wednesday, hitting $353.78. The company had a trading volume of 182,298 shares, compared to its average volume of 295,148. The company has a market capitalization of $15.80 billion, a price-to-earnings ratio of 15.60, a P/E/G ratio of 0.92 and a beta of 0.57. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82. The company has a 50-day moving average price of $364.28 and a 200 day moving average price of $357.68.

Analysts Set New Price Targets

UTHR has been the subject of several research analyst reports. Argus lifted their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. StockNews.com raised United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, January 16th. LADENBURG THALM/SH SH lifted their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. The Goldman Sachs Group upped their price target on United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research report on Friday, November 1st. Finally, HC Wainwright boosted their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $378.36.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.